Key studies on migraine treatment presented at the American Headache Society's 63rd Annual Virtual Scientific Meeting included results from trials of two emerging preventive therapies.
Dr Brian Grosberg, of the University of Connecticut School of Medicine, reviews late-phase trial data demonstrating the efficacy of the oral CGRP antagonists atogepant and rimegepant for migraine prevention. He also discusses the findings from three different analyses that looked at the so-called "wear-off" phenomenon reported by a small number of users of biologic agents.
Dr Grosberg also reports on a summary of data from the CaMEO survey indicating that oral preventive therapies for migraine are greatly underutilized despite high interest among patients. He reviews results from the OUTCOME study, which identifies patient groups that are most likely to hesitate to seek migraine care. He explains key takeaways from a survey of obstetricians-gynecologists that assessed their comfort level with managing migraine in new or expecting mothers.
Finally, Dr Grosberg shares results from a new patient satisfaction survey that reveals how patients viewed telehealth measures for migraine care accessed during the COVID-19 pandemic.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Migraine Highlights From 2021 AHS Virtual Scientific Meeting - Medscape - Jun 25, 2021.
Comments